Champiat S - Search Results

1

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.

Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, Chaput N, Eggermont A, Marabelle A, Soria JC, Ferté C. Champiat S, et al. Clin Cancer Res. 2017 Apr 15;23(8):1920-1928. doi: 10.1158/1078-0432.CCR-16-1741. Epub 2016 Nov 8. Clin Cancer Res. 2017. PMID: 27827313

2

[Immune-checkpoints: the new anti-cancer immunotherapies].

Ileana E, Champiat S, Soria JC. Ileana E, et al. Among authors: champiat s. Bull Cancer. 2013 Jun;100(6):601-10. doi: 10.1684/bdc.2013.1771. Bull Cancer. 2013. PMID: 23735730 Review. French.

3

[Immunotherapies and targeted therapies in medical oncology].

Rousseau B, Champiat S, Loirat D, Arrondeau J, Lemoine N, Soria JC. Rousseau B, et al. Among authors: champiat s. Bull Cancer. 2014 Jan 1;101(1):31-9. doi: 10.1684/bdc.2013.1865. Bull Cancer. 2014. PMID: 24333964 Review. French.

4

Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC.

Champiat S, Ileana E, Giaccone G, Besse B, Mountzios G, Eggermont A, Soria JC. Champiat S, et al. J Thorac Oncol. 2014 Feb;9(2):144-53. doi: 10.1097/JTO.0000000000000074. J Thorac Oncol. 2014. PMID: 24419410 Free article. Review.

5

Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy.

Champiat S, Ferté C, Lebel-Binay S, Eggermont A, Soria JC. Champiat S, et al. Oncoimmunology. 2014 Jan 1;3(1):e27817. doi: 10.4161/onci.27817. Epub 2014 Jan 16. Oncoimmunology. 2014. PMID: 24605269 Free PMC article.

6

Immune checkpoint inhibitors in advanced nonsmall cell lung cancer.

Helissey C, Champiat S, Soria JC. Helissey C, et al. Among authors: champiat s. Curr Opin Oncol. 2015 Mar;27(2):108-17. doi: 10.1097/CCO.0000000000000167. Curr Opin Oncol. 2015. PMID: 25602683 Review.

7

[Breaking immune tolerance in cancer].

Desbois M, Champiat S, Chaput N. Desbois M, et al. Among authors: champiat s. Bull Cancer. 2015 Jan;102(1):34-52. doi: 10.1016/j.bulcan.2014.12.002. Epub 2015 Jan 13. Bull Cancer. 2015. PMID: 25609492 Review. French.

8

Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab.

Hua C, Boussemart L, Mateus C, Routier E, Boutros C, Cazenave H, Viollet R, Thomas M, Roy S, Benannoune N, Tomasic G, Soria JC, Champiat S, Texier M, Lanoy E, Robert C. Hua C, et al. Among authors: champiat s. JAMA Dermatol. 2016 Jan;152(1):45-51. doi: 10.1001/jamadermatol.2015.2707. JAMA Dermatol. 2016. PMID: 26501224 Clinical Trial.

9

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.

Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, Izzeddine H, Marabelle A, Champiat S, Berdelou A, Lanoy E, Texier M, Libenciuc C, Eggermont AM, Soria JC, Mateus C, Robert C. Boutros C, et al. Among authors: champiat s. Nat Rev Clin Oncol. 2016 Aug;13(8):473-86. doi: 10.1038/nrclinonc.2016.58. Epub 2016 May 4. Nat Rev Clin Oncol. 2016. PMID: 27141885 Review.

10

The development of immunotherapy in older adults: New treatments, new toxicities?

Helissey C, Vicier C, Champiat S. Helissey C, et al. Among authors: champiat s. J Geriatr Oncol. 2016 Sep;7(5):325-33. doi: 10.1016/j.jgo.2016.05.007. Epub 2016 Jun 16. J Geriatr Oncol. 2016. PMID: 27318796 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

126 results

Search Page

Filters